Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Colorcon
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Bevasiranib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Bevasiranib: Sponsors, patents, clinical trial progress

Bevasiranib is an investigational drug.

There have been 5 clinical trials for Bevasiranib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Macular Degeneration, Choroidal Neovascularization, and Macular Edema. The leading clinical trial sponsors are OPKO Health, Inc. and [disabled in preview].

There are four US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for Bevasiranib
TitleSponsorPhase
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)OPKO Health, Inc.Phase 3
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMDOPKO Health, Inc.Phase 3
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular EdemaOPKO Health, Inc.Phase 2

See all Bevasiranib clinical trials

Clinical Trial Summary for Bevasiranib

Top disease conditions for Bevasiranib
Top clinical trial sponsors for Bevasiranib

See all Bevasiranib clinical trials

US Patents for Bevasiranib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bevasiranib   Start Trial Recombinant vectors Tocagen Inc. (San Diego, CA)   Start Trial
Bevasiranib   Start Trial Reverse thermal gels and uses therefor University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA)   Start Trial
Bevasiranib   Start Trial Reverse thermal gels and uses therefor University of Pittsburgh-Of the Commonwealth System of Higher Education (Pittsburgh, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
McKesson
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.